Loading...
In this manufacturer-funded study, researchers examined how many chronic migraineurs who do not respond to the first cycle of onabotulinumtoxinA will respond to the second or third cycle. The researchers used pooled data from two multicenter PREEMPT trials conducted in North America and Europe, both with a 4-week baseline period followed by two 12-week treatment cycles that were double-blinded, randomized, and placebo-controlled (onabotulinumtoxinA vs. saline injections). Subsequently, three 12-week treatment cycles were unblinded. This responder analysis was performed on the onabotulinumtoxinA arm (n=688).
After the first cycle of treatment, 49.3% of patients experienced a ≥50% reduction in headache days during at least one month. An additi…